henipavirus
hendra
viru
hev
nipah
viru
niv
recent
emerg
highli
pathogen
paramyxoviru
zoonos
whose
major
reservoir
natur
sever
speci
pteropid
fruit
bat
hev
caus
lethal
respiratori
diseas
enceph
hors
sever
respiratori
diseas
late
onset
enceph
human
total
hev
spillov
event
australia
includ
case
human
infect
fatal
sinc
niv
subsequ
emerg
peninsular
malaysia
caus
larg
outbreak
respiratori
diseas
pig
enceph
among
pig
farmer
later
shown
close
relat
hev
similar
hev
nearli
annual
outbreak
niv
infect
observ
niv
outbreak
associ
significantli
higher
case
fatal
rate
peopl
sever
outbreak
also
link
consumpt
raw
date
palm
sap
contamin
viru
well
humantohuman
transmiss
date
report
case
niv
infect
peopl
fatal
unusu
broad
speci
tropism
high
morbid
mortal
rate
well
lack
licens
therapeut
render
henipavirus
biolog
safeti
pathogen
potenti
biolog
threat
human
livestock
often
util
approach
antiviru
drug
design
block
viral
entri
via
small
molecul
peptid
neutral
monoclon
antibodi
mab
bind
viral
surfac
glycoprotein
uniqu
featur
major
paramyxovirus
requir
two
surfac
glycoprotein
host
cell
entri
class
fusion
f
glycoprotein
attach
glycoprotein
hn
hemagglutinin
h
case
henipavirus
g
glycoprotein
neither
hemagglutin
neuraminidas
activ
henipaviru
g
glycoprotein
engag
host
cell
membran
protein
receptor
initi
interact
believ
suffici
trigger
fmediat
fusion
event
viral
envelop
host
cell
membran
lead
viru
entri
absenc
avail
vaccin
antivir
drug
neutral
hmab
offer
possibl
effect
pre
andor
postexposur
treatment
mani
import
human
viral
infect
previous
sever
hmab
isol
use
recombin
solubl
hendra
viru
g
hevg
glycoprotein
antigen
pan
larg
antibodi
librari
among
hmab
deriv
gener
heavi
chain
random
mutat
light
chain
shuffl
show
improv
bind
hevg
clone
equal
higher
bind
affin
clone
select
character
convert
format
hmab
abl
crossreact
nivg
hevg
vitro
inhibitori
concentr
less
ngml
ngml
nipah
viru
hendra
viru
respect
capabl
neutral
avail
isol
hev
niv
anim
diseas
model
shown
capabl
protect
ferret
lethal
niv
challeng
well
african
green
monkey
agm
lethal
hev
challeng
time
frame
even
hour
post
viral
exposur
respect
light
experiment
success
postexposur
treatment
niv
hev
infect
sinc
administ
compassion
use
basi
two
individu
australia
high
risk
hev
exposur
hev
spillov
anoth
person
expos
hev
use
compassion
use
protocol
individu
laboratori
exposur
niv
unit
state
case
none
individu
show
symptom
hev
niv
infect
time
administr
individu
remain
good
health
date
altogeth
fulli
human
mab
show
promis
potenti
prophylact
therapeut
agent
henipaviru
infect
appear
suitabl
control
safeti
trial
human
fulli
character
bind
epitop
well
bind
recognit
mechan
determin
present
crystal
structur
complex
globular
head
domain
hevg
fab
domain
close
deriv
featur
ident
heavi
chain
similar
light
chain
structur
reveal
molecular
mechan
neutral
crossreact
provid
basi
improv
includ
efficaci
enhanc
escap
mutant
prevent
addit
present
structur
inform
may
aid
develop
henipaviru
vaccin
specif
entri
inhibitor
head
domain
hevg
residu
produc
use
baculoviru
express
system
fab
domain
express
cell
protein
complex
gener
mix
hevsg
hmab
molar
ratio
follow
hour
incub
purif
sizeexclus
chromatographi
sec
peak
fraction
contain
complex
collect
use
crystal
obtain
two
crystal
form
complex
use
molecular
replac
determin
structur
resolut
space
group
resolut
space
group
tabl
one
complex
per
asymmetr
unit
crystal
form
overal
structur
two
crystal
form
similar
figur
region
contain
hevg
molecul
complementar
determin
heavi
chain
fab
superimpos
rmsd
atom
two
fab
structur
exclud
superimpos
rmsd
atom
differ
two
structur
angl
rest
fab
consequenti
caus
slight
differ
buri
interfac
area
crystal
form
crystal
form
howev
interfac
residu
core
region
crystal
form
remaind
report
figur
use
structur
fab
bind
similar
area
hevg
figur
compos
hydrophob
central
caviti
hydrophil
rim
interestingli
fab
approach
hevg
central
caviti
similar
angl
direct
gh
loop
figur
interfac
involv
fab
residu
mostli
locat
well
three
residu
one
residu
one
residu
figur
long
protrud
residu
adopt
conform
includ
stalk
tip
central
hydrophob
hevgfab
contact
form
embed
tip
hydrophob
hevg
receptorbind
caviti
simul
anneal
omit
electron
densiti
map
region
illustr
figur
among
eight
residu
tip
surround
hevg
surround
hevg
surround
hevg
surround
hevg
surround
hevg
figur
addit
side
chain
fab
stack
togeth
form
top
layer
stack
hydrogen
bond
hevg
surround
hydrophil
hevgfab
contact
involv
residu
notabl
form
saltbridg
hevg
hydrogen
bond
also
form
hevg
well
hevg
respect
figur
hevg
residu
engag
list
figur
interestingli
fab
bind
induc
signific
conform
chang
hevg
rmsd
posit
unbound
fabbound
hevg
previous
identifi
hevg
mutat
report
affect
bind
part
epitop
figur
suggest
mutat
might
affect
overal
hevg
structur
hevg
head
domain
fab
strictli
monomer
interestingli
two
protein
mix
togeth
first
form
heterodimer
complex
oligomer
solut
inde
sec
assay
indic
hour
mix
complex
migrat
posit
correspond
twice
origin
size
gelfiltr
column
explan
phenomenon
provid
crystal
pack
complex
two
copi
fab
hevg
assembl
heterotetram
figur
note
heterotetramer
fabhevg
complex
assembl
observ
crystal
form
illustr
figur
heterotetramer
assembl
gener
twofold
crystallograph
symmetri
axi
two
fab
molecul
contact
buri
approxim
surfac
area
side
two
hevg
molecul
remain
separ
importantli
addit
contact
area
fab
light
chain
elbow
region
hevg
molecul
interact
complex
buri
bind
partner
figur
blue
region
thu
total
surfac
area
occlud
side
interfac
two
complex
within
heterotetramer
complex
hevg
form
extens
interact
interfac
render
stabl
assembl
shown
fig
total
hevg
surfac
region
involv
interact
almost
one
interact
howev
physiolog
relev
tetramer
assembl
result
crosslink
mabg
complex
viral
membran
need
studi
interact
receptorbind
surfac
hevg
includ
central
hydrophob
caviti
surround
hydrophil
rim
resembl
gh
loop
shape
insert
angl
hevg
caviti
figur
gh
loopcontact
residu
hevg
also
particip
bind
figur
c
unlik
ephrin
bind
caus
signific
conform
chang
hevg
interestingli
although
tip
gh
loop
target
pocket
hevg
central
caviti
use
slightli
differ
residu
anchor
strategi
shown
figur
left
right
ephrin
gh
loop
insert
four
hydrophob
hevg
pocket
occupi
half
hevg
caviti
insert
first
three
pocket
figur
among
ephrin
strikingli
similar
addit
insert
emb
half
hevg
caviti
side
chain
extend
direct
gh
loop
reach
fourth
pocket
instead
embed
groov
defin
hevg
hydrogen
bond
hevg
lock
posit
prevent
withdraw
bind
caviti
sinc
contact
resid
hevg
mutat
v
could
presum
enhanc
interact
hevg
summari
bind
hevg
util
high
affin
lockandkey
mode
without
induc
conform
chang
hevg
although
mab
origin
isol
hevg
demonstr
potent
neutral
capac
niv
hev
inde
vitro
bind
measur
use
biolay
infetrometri
tabl
document
display
higher
bind
affin
nivg
hevg
due
high
similar
nivg
hevg
presum
bind
nivg
hevg
similar
manner
examin
structur
highlight
small
structur
differ
may
explain
increas
affin
nivg
upon
superimposit
nivg
hevg
found
three
residu
mab
contact
region
differ
among
hevg
part
bind
pocket
replac
two
hydrophob
residu
valin
phenylalanin
nivg
figur
increas
hydrophob
area
like
strengthen
predominantli
hydrophob
interact
g
protein
enhanc
neutral
activ
panel
deriv
gener
light
chain
shuffl
heavi
chain
random
mutagenesi
among
report
equal
slightli
higher
affin
henipaviru
g
glycoprotein
comparison
other
biolay
interferometri
tabl
hand
indic
actual
slightli
higher
bind
affin
nivg
kd
nm
hevg
kd
nm
kd
nm
nm
respect
primari
sequenc
overal
highli
similar
featur
ident
heavi
chain
provid
one
bind
residu
differ
light
chain
amino
acid
part
interfac
figur
indirectli
account
small
differ
bind
affin
hevg
contact
residu
conserv
structur
inform
obtain
complex
could
also
appli
explain
mechan
neutral
neutral
assay
perform
effici
mab
wild
type
niv
hev
three
fold
higher
fab
fab
highlight
import
dimer
confer
fc
region
notabl
effici
fab
within
rang
slightli
lower
fab
figur
suggest
neutral
effici
may
also
affect
factor
protein
stabil
flexibl
detail
character
bind
hmab
viru
infecti
niv
hev
use
gener
antibodi
neutral
escap
mutant
incub
cultur
high
titer
viru
presenc
hmab
fab
fragment
fab
fragment
mab
passag
result
viru
stock
plaqu
purifi
test
neutral
efficaci
g
f
glycoprotein
gene
minimum
five
plaqu
escap
variant
sequenc
order
identifi
mutat
associ
antibodi
escap
phenotyp
niv
escap
mutant
ten
plaqu
escap
mutant
contain
singl
amino
acid
chang
locat
hev
mutant
escap
neutral
contain
singl
amino
acid
mutat
locat
figur
clone
viru
stock
escap
mutant
niv
hev
contrast
wildtyp
niv
hev
longer
neutral
antibodi
concentr
exceed
figur
addit
clone
viru
stock
escap
mutant
analyz
singl
round
growth
assay
comparison
wildtyp
hev
niv
vero
cell
figur
neutral
escap
mutant
grew
effici
equal
titer
wildtyp
viru
vero
cell
notic
howev
passag
neutral
resist
virus
rel
slow
develop
cytopath
effect
cpe
whole
genom
sequenc
perform
identifi
addit
mutat
two
escap
compar
parent
strain
sequenc
report
attach
support
materi
report
hev
escap
variant
contain
anoth
silent
mutat
p
gene
addit
mutat
g
gene
niv
escap
variant
contain
mutat
n
gene
end
gene
l
gene
addit
mutat
g
gene
thu
escap
certainli
due
mutat
g
gene
case
hev
escap
mutant
whole
genom
analysi
parent
viru
stock
escap
mutant
identif
snp
indic
like
reason
slow
appear
cpe
presenc
need
resist
viru
amplif
level
suffici
cellcel
fusion
combin
bind
affin
measur
tabl
structur
provid
clue
escap
mechan
escap
mutant
figur
interestingli
affin
g
protein
antibodi
increas
mutat
nivg
decreas
mutat
hevg
residu
locat
bottom
nivg
caviti
interact
addit
methyl
group
would
like
result
intim
interact
gh
loop
result
lower
kd
valu
due
decreas
dissoci
koff
rate
furthermor
bind
benefit
slightli
antibodi
substitut
intriguingli
locat
loop
g
protein
outsid
receptormab
bind
region
suggest
mutat
affect
fabgprotein
interact
indirect
pathway
figur
form
saltbridg
two
residu
mutat
would
like
caus
conform
chang
caus
rearrang
sever
residu
includ
thu
hinder
insert
gh
loop
inde
observ
associ
rate
kon
tabl
mutant
antibodi
decreas
similarli
howev
conform
chang
would
affect
overal
ephrin
bind
less
seem
similar
rearrang
take
place
even
wildtyp
g
protein
figur
inde
pocketform
residu
figur
elimin
two
saltbridg
result
substitut
might
even
slight
stabil
effect
gh
loop
insert
accordingli
observ
dissoci
rate
koff
bind
hevg
mutant
slightli
decreas
dissoci
rate
bind
antibodi
increas
summari
mutat
g
protein
favor
bind
compar
mab
bind
consist
neutralizationescap
phenotyp
target
viral
surfac
spike
protein
power
strategi
develop
neutral
mab
similar
target
henipaviru
g
protein
number
potent
antibodi
develop
spike
glycoprotein
sarsassoci
coronaviru
hemagglutinin
glycoprotein
influenza
viru
envelop
glycoprotein
hiv
epitop
recogn
antibodi
often
function
associ
viral
entri
mechan
eg
attach
membran
fusion
reduc
occurr
escap
mutant
instanc
hiv
epitop
target
neutral
antibodi
locat
four
region
receptor
bind
site
rb
fusion
associ
membraneproxim
extern
region
mper
region
conserv
glycan
structur
glycan
associ
loop
region
influenza
epitop
locat
fusion
associ
stem
region
sialic
acid
bind
pocket
region
henipavirus
member
paramyxoviru
famili
attach
fusion
function
exert
two
differ
protein
render
possibl
epitop
locat
rb
fusionrel
region
site
associ
transduc
fusiontrigg
signal
attach
fusion
protein
past
year
crystal
structur
complex
viral
rb
neutral
antibodi
determin
includ
target
sar
glycoprotein
rb
target
influenza
viru
sialic
acid
bind
pocket
target
site
review
interestingli
mani
exampl
antibodi
cdr
region
mimic
conform
bind
region
cellular
receptor
either
protein
carbohydr
amongst
similar
structur
structur
target
influenza
viru
sialic
acid
bind
site
conserv
shallow
groov
three
mab
use
bind
target
groov
compar
contact
larger
conserv
region
rb
without
interact
surround
variabl
region
account
greater
neutral
breadth
strategi
could
appli
improv
antibodi
featur
long
residu
kabat
number
adapt
provid
interest
exampl
antibodi
circumv
obstacl
reach
target
epitop
one
challeng
viral
epitop
target
epitop
sometim
hidden
either
behind
heavi
glycosyl
deep
caviti
anoth
exampl
long
form
antibodi
hiv
residu
extrem
case
categori
hiv
neutral
antibodi
contain
axeshap
mani
test
therapeut
strategi
prevent
andor
treat
infect
diseas
caus
henipavirus
varieti
wellcharacter
anim
model
effect
recent
postexposur
therapeut
option
highli
effect
anim
model
clear
potenti
futur
approv
human
use
applic
hmab
report
success
nonhuman
primat
model
hev
infect
particularli
encourag
exhibit
excel
distribut
halftim
day
elimin
halftim
day
agm
evid
hevspecif
patholog
observ
anim
infecti
hev
could
recov
studi
reveal
hmab
prevent
widespread
hev
dissemin
viru
challeng
subject
first
success
postexposur
vivo
therapi
hev
first
nonhuman
primat
hev
spillov
occurr
queensland
australia
two
individu
consid
high
risk
hev
infect
hmab
request
australian
health
author
administ
two
individu
compassion
use
therapeut
option
even
though
human
safeti
test
carri
recommend
use
human
instanc
administ
individu
prior
hev
diagnosi
onset
clinic
diseas
dose
mgkg
suffici
achiev
high
serum
concentr
date
individu
remain
healthi
evid
hev
infect
report
antibodi
appear
well
toler
administ
unexpect
sinc
human
mab
hmab
preclin
develop
stage
unit
state
australia
part
continu
character
sought
provid
molecular
detail
ephrin
receptor
block
activ
determin
crystal
structur
nearli
ident
deriv
possess
crossreact
neutral
henipaviru
g
bind
activ
ident
heavi
chain
sequenc
g
glycoprotein
bind
loop
domain
structur
report
complex
reveal
molecular
mechan
underl
except
crossreact
neutral
potenc
antibodi
bind
hmab
g
glycoprotein
involv
singl
loop
heavi
chain
hydrophob
amino
acid
residu
occupi
pocket
g
ephrin
receptor
engag
receptor
bind
clear
central
caviti
henipaviru
g
glycoprotein
receptorbind
face
vital
viral
attach
infect
crystal
structur
protein
complex
know
block
access
caviti
feasibl
effici
way
inhibit
henipaviru
attach
infect
specif
peptid
smallmolecul
inhibitor
viral
attach
glycoprotein
design
base
structur
data
exampl
exist
pocket
g
glycoprotein
caviti
use
target
structurebas
comput
screen
anoth
approach
would
screen
compound
librari
use
protein
interact
primari
assay
optim
initi
hit
better
fit
bind
caviti
data
present
consist
initi
step
henipaviru
entri
model
propos
earlier
base
analysi
g
glycoprotein
ephrin
receptorg
glycoprotein
complex
structur
import
new
hmab
complex
structur
provid
import
inform
lead
potenti
antibodi
improv
two
regard
increas
antibodi
affin
g
glycoprotein
order
obtain
even
higher
effici
manipul
interact
interfac
order
reduc
potenti
occurr
escap
mutant
difficulti
second
aspect
lie
observ
affin
attach
protein
receptor
strictli
correl
infect
effici
henipavirus
thu
mutat
affect
henipaviru
g
glycoprotein
bind
affin
ephrin
receptor
mab
similar
degre
could
still
allow
potenti
escap
inde
observ
even
though
remark
overlap
epitop
receptor
bind
region
henipaviru
g
two
escap
mutant
variant
hev
niv
contain
g
glycoprotein
mutat
respect
identifi
vitro
manipul
repeat
passag
viru
allow
replic
presenc
neutral
antibodi
routin
use
approach
gener
escap
variant
examin
mean
map
epitop
detail
mab
neutral
mechan
howev
emphas
appear
escap
variant
observ
vivo
efficaci
test
hev
niv
date
like
explain
fact
high
dose
mab
util
similar
mab
dose
use
peopl
prophylact
treatment
rsv
infect
f
synagispalivizumab
addit
effect
appear
virtu
abil
slow
progress
dissemin
viru
within
challeng
host
allow
host
effect
window
mount
innat
adapt
immun
respons
eventu
prevent
lethal
diseas
outcom
taken
togeth
success
hmab
vivo
effect
postexposur
treatment
henipaviru
diseas
two
differ
wellcharacter
anim
model
ferret
nonhuman
primat
along
new
detail
structur
find
viral
g
glycoprotein
bind
featur
help
explain
superior
crossreact
neutral
activ
facilit
effort
aim
obtain
approv
human
use
applic
treat
accident
exposur
hev
niv
infect
solubl
head
domain
amino
acid
residu
hevg
clone
vector
express
baculoviru
express
system
bd
bioscienc
plasmid
transfect
cell
use
cellfectin
invitrogen
baculogold
linear
baculoviru
dna
bd
bioscienc
viru
amplifi
cell
three
round
reach
proper
titer
appli
cell
final
express
volum
infect
ratio
infect
cell
harvest
hour
infect
cell
media
contain
hevg
protein
purifi
use
ionexchang
sizeexclus
chromatographi
ge
bioscienc
solubl
fab
express
purifi
describ
complex
obtain
mix
two
protein
molar
ratio
pass
superdex
column
ge
bioscienc
fraction
contain
protein
collect
concentr
mgml
hb
buffer
mm
hepe
ph
mm
kcl
initi
crystal
condit
obtain
wizard
iii
emerald
biosystem
procomplex
qiagen
screen
use
robot
screen
ttp
labtech
mosquito
sever
round
optim
use
hang
drop
vapor
diffus
room
temperatur
two
crystal
form
obtain
condit
peg
hepe
ph
crystal
frozen
liquid
nitrogen
glycerol
cryoprotect
diffract
data
collect
beamlin
necat
advanc
photon
sourc
argonn
nation
laboratori
data
imag
process
use
program
structur
determin
molecular
replac
pdb
id
nivg
hmab
hiv
viru
phaser
coot
phenix
refin
program
suit
phenix
use
structur
determin
model
build
refin
detail
crystallograph
analysi
present
tabl
neutral
resist
niv
hev
mutant
gener
incub
viru
mab
niv
niv
hev
respect
media
h
inocul
onto
vero
cell
presenc
mab
concentr
develop
cytopath
effect
cpe
monitor
h
progeni
virus
harvest
mab
treatment
repeat
two
addit
time
cpe
develop
slowli
passag
passag
virus
plaqu
purifi
presenc
mab
neutral
resist
virus
isol
experi
perform
duplic
glycoprotein
fusion
protein
gene
individu
plaqu
experi
sequenc
neutral
titer
wild
type
neutral
resist
viru
determin
micro
neutral
assay
briefli
mab
fab
serial
dilut
twofold
incub
wild
type
wt
neutral
resist
niv
hev
h
viru
antibodi
ad
plate
vero
well
per
antibodi
dilut
well
check
cpe
day
post
infect
neutral
titer
determin
mab
concentr
least
well
show
cpe
growth
curv
perform
inocul
cell
cultur
niv
hev
escap
mutant
multipl
infect
moi
h
cell
wash
time
pb
overlaid
medium
viru
sampl
obtain
variou
time
point
infect
store
viral
titer
determin
bind
kinet
wild
type
mutant
g
protein
antibodi
measur
biolay
interferometri
blitz
instrument
fortebio
ninta
biosensor
use
immobil
hexahistidin
fuse
antibodi
protein
kinet
paramet
kon
koff
affin
kd
calcul
nonlinear
fit
blitz
instrument
data
use
blitz
softwar
viru
mix
trizol
ls
rna
extract
follow
manufactur
guidelin
illumina
truseq
cdna
librari
prepar
total
rna
omit
polya
select
step
librari
subject
half
miseq
run
use
cycl
kit
pair
end
sequenc
qualiti
control
tool
high
throughput
sequenc
fastqc
java
standalon
program
download
babraham
bioinformat
institut
http
wwwbioinformaticsbabrahamacukprojectsfastqc
fastq
file
check
qualiti
result
wt
hev
wt
niv
read
map
respect
refer
genom
use
clc
genom
workbench
use
default
paramet
consensu
sequenc
extract
use
refer
genom
read
result
sequenc
mutant
sampl
map
consensu
sequenc
mutant
extract
align
wt
use
clc
genom
workbench
default
paramet
henipaviru
g
attach
glycoprotein
sequenc
align
clc
main
workbench
use
default
paramet
gap
open
cost
gap
extens
cost
molecular
represent
produc
pymol
delano
scientif
llc
figur
prepar
use
adob
illustr
adob
photoshop
